Chandan's Jeena Sikho tie-up exceeds Rs 1.50 crore monthly
Key highlights
- Chandan's Jeena Sikho partnership has crossed a Rs 1.50 crore monthly revenue run-rate.
- Approximately 80% of Jeena Sikho locations are operational across 23 states and more than 100 cities.
- Chandan's B2B segment represented 36.7% of standalone revenue and grew 106.5% year on year in Q2 FY27.
- Jeena Sikho subscribed to 18 lakh of the 44.50 lakh warrants issued in Chandan's October 2025-approved preferential issue.
powered by IRIS

Chandan's exclusive five-year diagnostics partnership with Jeena Sikho Lifecare Limited has crossed a monthly revenue run-rate of Rs 1.50 crore, while about 80% of partner locations are operational across 23 states and more than 100 cities. Chandan establishes and operates its own laboratories inside or adjacent to the partner's hospitals and clinics.
Know Chandan Healthcare inside out
Results, valuation, peers and who's buying, in one view.
What has Chandan achieved through the Jeena Sikho partnership?
Chandan has crossed a monthly revenue run-rate of Rs 1.50 crore from its Jeena Sikho relationship. The investor presentation says monthly revenue continues to rise as the company brings the remaining partner locations into operation over the coming months. This is a monthly run-rate disclosure rather than a separately reported quarterly or annual revenue figure for the partnership.
Approximately 80% of Jeena Sikho locations are operational, according to the presentation. The arrangement covers the partner's existing hospitals and clinics in 23 states and more than 100 cities, and extends automatically to facilities Jeena Sikho opens in future. Chandan does not disclose the total number of partner sites, so the number represented by the remaining roughly 20% is not available.
The partnership is part of Chandan's business-to-business, or B2B, institutional channel. In Q2 FY27, B2B contributed 36.7% of standalone revenue, compared with 34.5% for business-to-consumer, or B2C, retail diagnostics and 28.8% for business-to-government, or B2G, public-private partnership activity.
How is Chandan's Jeena Sikho arrangement structured?
Chandan is the exclusive diagnostics partner for all existing and upcoming Jeena Sikho hospitals and clinics for five years. The company provides end-to-end pathology and radiology services for inpatient and outpatient departments through laboratories located within or adjacent to the partner facilities.
These are company-owned laboratories operated by Chandan, rather than franchise collection points. Under Chandan's franchise model, a local franchisee collects samples and routes them to the nearest Chandan laboratory, whereas the Jeena Sikho model places Chandan-operated diagnostics capacity at a hospital or clinic location.
The presentation says the balance of Jeena Sikho locations is targeted for operational rollout in the coming months. That timeline follows the approximately 80% rollout already completed, but Chandan provides neither a final completion date nor a location-by-location rollout schedule.
How does the partnership fit Chandan's B2B revenue mix?
B2B was Chandan's largest disclosed revenue segment in Q2 FY27, accounting for 36.7% of standalone revenue and growing 106.5% year on year. B2C contributed 34.5% and grew 23.8%, while B2G accounted for 28.8% and grew 17.2%, making B2B the fastest-growing of the three reported channels.
Chandan links its B2B activity to more than 230 hospitals, clinics, corporates, insurers, third-party administrators and laboratories, alongside more than 200 institutional affiliations. The Jeena Sikho agreement is identified as an exclusive five-year diagnostics partnership within this channel, which also includes employee health programmes, insurer examinations and specialised testing for referral laboratories.
Chandan says B2B contracts provide recurring volumes and have receivable cycles of one to two months. The presentation does not separately disclose the Jeena Sikho contract's receivable cycle, revenue contribution to total B2B sales, or the share of B2B growth attributable to the partnership.
Got a follow-up? Ask IRIS
What network supports Chandan's hospital diagnostics rollout?
Chandan's network includes 25 Comprehensive Diagnostic Centres, 19 Diagnostic Centres, 25 standalone laboratories, two Central Reference Laboratories and more than 685 franchise centres. The two Central Reference Laboratories, in Lucknow and Haldwani, process high-end hormonal, biochemistry and specialised tests rather than receiving direct patient footfall.
The installed clinical estate includes 16 magnetic resonance imaging, or MRI, machines, 20 computed tomography, or CT, machines and 28 ultrasound machines. It also includes 35 digital X-ray machines, nine bone mineral density units, three mammography units, 54 electrocardiogram machines and 22 treadmill test systems, which align with the pathology, radiology and imaging services offered at partner hospitals.
Chandan reports 16 laboratories accredited by the National Accreditation Board for Testing and Calibration Laboratories, or NABL, eight centres accredited by the National Accreditation Board for Hospitals and Healthcare Providers, or NABH, and 30 radiology centres licensed by the Atomic Energy Regulatory Board, or AERB. It also says ISO 9001:2015 quality management systems cover all centres, without specifying the accreditation status of individual Jeena Sikho locations.
What does Jeena Sikho's warrant subscription show?
Jeena Sikho subscribed to 18 lakh warrants from the 44.50 lakh warrants issued under Chandan's preferential issue approved in October 2025. The subscription is disclosed as capital-markets participation by the hospital-network partner in Chandan's warrant issue.
The presentation does not disclose the warrant exercise price, consideration, conversion timing or resulting number of shares. It also does not say that the 18 lakh-warrant subscription changes the five-year exclusive diagnostics arrangement or its rollout terms.
Conclusion
Chandan's Jeena Sikho arrangement combines a five-year exclusive mandate with company-operated laboratories at a hospital and clinic network spanning 23 states and more than 100 cities. The Rs 1.50 crore-plus monthly revenue run-rate and approximately 80% operational rollout place the partnership within a B2B segment that represented 36.7% of standalone revenue and grew 106.5% year on year in Q2 FY27.
The next disclosed development is the rollout of the remaining partner locations over the coming months. Chandan has not given a site count or completion date, so progress in operationalising the final approximately 20% of locations remains the stated item to watch.


